Reports
The following list of reports reflects the latest in findings and outcomes in medical research as presented at major medical meetings and published peer-reviewed medical journals. In this section you can view reports from important congresses as well as summaries of some recently published journal articles. Please let us know if you have a particular area of interest you would like to see covered.
PRIORITY PRESS - 45th Annual Meeting of the American Society of Clinical Oncology
Update on Emesis Control for Chemotherapy Patients: Improving Quality of Life
Orlando, Florida / May 29-June 2, 2009
Orlando - The failure to understand and aggressively manage the risk of chemotherapy-induced nausea and vomiting represents an unnecessary and avoidable burden for patients with cancer. The frequency with which clinicians underestimate the...
PRIORITY PRESS - 45th Annual Meeting of the American Society of Clinical Oncology
Novel Maintenance Strategies in the Care of Patients with Non-small Cell Lung Cancer
Orlando, Florida / May 29-June 2, 2009
Orlando - Evidence of meaningful clinical benefit from maintenance therapy in advanced non-small cell lung cancer has led to a paradigm shift in the treatment of this malignancy. In a series of three consecutive studies, maintenance...
PHYSICIAN PERSPECTIVE - Viewpoint based on presentations from the Toronto Myelodysplastic Syndromes Symposium: Progress and Challenges
Pathophysiology of Myelodysplastic Syndromes and Treatment Strategies to Change its Natural History
Toronto, Ontario / May 21-22, 2009
INTRODUCTION Treating patients with myelodysplastic syndromes (MDS) beyond supportive care has become a viable goal. As the pathobiology of MDS is unravelled, new therapies become available to treat these complex bone marrow failure...
PRIORITY PRESS - 104th Annual Meeting of the American Urological Society
Relearning and Refining the Lessons from the Prostate Cancer Prevention Trial
Chicago, Illinois / April 25-30, 2009
Chicago - Few clinical trials have met with such diverse reactions as those that followed the findings of the PCPT (Prostate Cancer Prevention Trial). The trial represented an unprecedented triumph in cancer prevention, demonstrating a 25%...
PRIORITY PRESS - 104th Annual Meeting of the American Urological Association
Androgen Deprivation Therapy for Prostate Cancer: From Hormonal Agonism to Antagonism
Chicago, Illinois / April 25-30, 2009
Chicago - Androgen deprivation therapy (ADT) has become an integral component of treatment for many patients with hormone-sensitive advanced prostate cancer. Multiple studies have shown that ADT blunts the progression of prostate cancer,...
MEDICAL FRONTIERS - 6th Annual ENETS Conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease
Paradigm Shift in the Treatment of Well-differentiated Neuroendocrine Tumours
Granada, Spain / March 5-7, 2009
Granada - The treatment of choice for primary neuroendocrine tumours (NETs) is surgery, but once metastatic disease occurs, options are limited. Management has generally focused on controlling symptoms using somatostatin analogues....
MEDI-NEWS Based on 2009 ASCO/AUA Guideline
Prostate Cancer Prevention with 5-alpha Reductase Inhibitors: Clinical Guideline and Recommendations
March 2009
For many types of cancer, prevention remains a challenge because of an incomplete understanding of potentially modifiable risk factors. With respect to prostate cancer, an opportunity for chemoprevention arose from the recognition that...
MEDICAL FRONTIERS San Antonio Breast Cancer Symposium
TEAM Trial: Update on Adjuvant Therapy in Early Breast Cancer
San Antonio, Texas / December 10-14, 2008
{{San Antonio}} - More than 20 years ago, the National Surgical Adjuvant Breast and Bowel Project B-09 (NSABP B-09) trial showed that adding tamoxifen to adjuvant chemotherapy significantly improved disease-free survival (DFS) in patients...
PRIORITY PRESS - 9th Annual Society of Urologic Oncology Winter Meeting
Advances in Androgen-deprivation Therapy for Prostate Cancer
Bethesda, Maryland / December 4-6, 2008
In prostate cancer patients requiring androgen-deprivation therapy (ADT), gonadotropin-releasing hormone (GnRH) antagonists achieve androgen suppression more rapidly and without the testosterone surge and microsurge that accompany...